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This Month in the Journal
The Journal is sorry to report that Dr. Norman Spencer
(a.k.a. Harrison Ford) will not be presenting his work
on DNA repair at the ASHGmeeting this year.Wewould
still like to thank him for accurately portraying the glam-
orous life of a geneticist in the movieWhat Lies Beneath.
We at the editorial office screened the movie in the hopes
of catching a glimpse of the Journal, since the movie
studio asked permission to use it on the set. Although
positive identification was difficult because of glare off
the Journal’s cover, we think that it was sitting next to
another genetics journal, which will remain nameless.
Despite our fleeting big-screen debut, the movie got four
thumbs up and two screams from us.
This month in the Journal, Frederick Moore and Re-
nee Reijo-Pera (p. 543), present an editorial on mtDNA
and male sperm motility. They discuss the findings, by
Ruiz-Pesini et al. (p. 682), that mtDNA haplogroup T
is associated with low sperm motility and that this may
be due to slight decreases in the activity of the oxidative
phosphorylation system in this haplogroup. In addition
to providing new information about untreatable male
subfertility, this work implicates mtDNA variation in the
phenotypic modulation of other disorders.
Iron-Frataxin Multimers, by Adamec et al.
(p. 549)
Blame it on free radicals again! Evidence of oxidative
damage, as well as iron-storage problems, are evident in
patients with Friedrich ataxia (FRDA), but the expla-
nation for this damage has not been understood. Defects
in the mitochondrial protein frataxin are the primary
cause of FRDA, an autosomal recessive neuro- and car-
dio-degenerative disease, but the relationship between
frataxin and oxidative damage has been unclear. Grazia
Isaya and colleagues have done extensive experimenta-
tion to demonstrate that frataxin is involved in iron se-
questration. They find that frataxin complexes into 60-
mers in an iron-dependent fashion. Although frataxin
monomer cannot bind iron, the multimer can sequester
an estimated 3,000 iron atoms in a bioavailable form.
The multimers are not simply nonspecific frataxin ag-
gregates, because (1) the multimerization is specifically
induced by iron, (2) it occurs in an ordered process, and
(3) the multimers can be fractionated, in complex with
iron, from yeast. Adamec et al. propose that this iron-
sequestration function is important for iron bioavaila-
bility in mitochondria and that loss of this function in
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patients with FRDA leaves them susceptible to iron-in-
duced oxidative damage.
Turner Syndrome Neurocognitive Phenotype, by Ross
et al. (p. 672); and VCX in X-Linked Mental
Retardation, by Fukami et al. (p. 563)
Rather than a nonspecific mental retardation, the cog-
nitive defects associated with Turner syndrome are lim-
ited to motor function, visual-spatial abilities, nonverbal
memory, visual-perceptual abilities, and attention. Al-
though there are likely to be hormonal and environ-
mental influences on this phenotype, some of the defects
are likely to result from direct genetic effects. JudithRoss
and colleagues (p. 672) have studied patients with partial
monosomy for Xp and have identified a genetic region
that is associated with the Turner syndrome neurocog-
nitive phenotype. This region maps to distal Xp22.3 and
falls within the pseudoautosomal region PAR1. Also
mapping to Xp22.3 is the VCX-A gene, which is deleted
in males with X-linked nonspecific mental retardation.
This gene was identified by Fukami et al. (p. 563), who
employed a procedure similar to that used by Ross et
al. Could the cognitive defects in Turner syndrome be
genetically linked to those in X-linked nonspecific men-
tal retardation? The critical regions identified in the two
studies do not directly overlap. However, larger dele-
tions in the Xp region can be associated with both dis-
orders, and it is tempting to speculate that some genes
play a modulating role in the cognitive deficits of both
disorders.
Genetic Polymorphisms and Down Syndrome Risk, by
Hobbs et al. (p. 623)
Folate metabolism is intimately involved in DNA syn-
thesis and the proper methylation of DNA. Methylene-
tetrahydrofolate reductase (MTHFR) and methionine
synthase reductase (MTRR) catalyze reactions in the bi-
ochemical pathway that generates the major methyl do-
nor for DNA, RNA, protein, and phospholipid meth-
ylation. Folate deficiency is associated with several DNA
defects, including DNA strand breaks, altered recom-
bination, abnormal DNAmethylation, and chromosome
missegregation. This has led Jill James and colleagues to
study the relationship between MTHFR, MTRR, and
Down syndrome. They have wonderedwhether defective
folate metabolism would lead to increased nondisjunc-
tion and, therefore, to Down syndrome. In this issue,
they present a study in which they calculated the ma-
ternal risk of Down syndrome in association with poly-
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morphisms in the genes for MTHFR and MTRR. They
found that both the 677CT polymorphism in MTHFR,
which reduces the enzyme’s activity, and the 66AG poly-
morphism in MTRR increase the risk of having a child
with Down syndrome. In combination, the polymor-
phisms had an additive effect, giving a 4.08-fold-in-
creased risk of Down syndrome. It is also possible that
a folate deficiency may exacerbate the effect of these
polymorphisms and may increase this risk even further.
The association of maternal MTHFR and MTRR var-
iation with Down syndrome provides a possible link
between intermediary metabolism and nondisjunction.
Ancestry of Icelandic Y Chromosomes, by Helgason
et al. (p. 697)
In theMarch 2000 issue ofAJHG (66:999–1016), Agnar
Helgason and colleagues examined mtDNA lineages
from modern Icelanders and found that the majority of
founding females for the Icelandic population came from
the British Isles. In a supplemental study, they examined
the Y-chromosomal lineage for the same population, and
they report the results in this issue (p. 697). Through an
analysis of diallelic and microsatellite variation in Ice-
landers, they have developed a phylogenetic network for
the Y chromosomes of this population. Comparison of
the Icelandic Y-chromosome variation with that of mod-
ern Scandinavian and Gaelic populations has identi-
fied a closer relationship between the Icelandic and Scan-
dinavian chromosomal pools than between the Icelandic
and Gaelic pools. These results suggest that the male
founder lineages for the Icelandic population were
largely Scandinavian; this is in contrast to the female
founders, who were largely Gaelic. Together, these stud-
ies correlate with historical evidence that suggests that
male Norse invaders of the British Isles eventually in-
termarried with the resident females and that some of
these family groups went on to settle Iceland.
Report (PPH1 Is BMPR2), by Deng et al. (p. 737)
This month in the Journal,Deng et al. show that patients
with familial primary pulmonary hypertension (PPH)
have mutations in the bone morphogenetic protein re-
ceptor II (BMPR2) gene. PPH is a very serious, pro-
gressive condition characterized by lesions that cause
constriction of the pulmonary arterial blood vessels. The
resulting hypertension leads to heart failure and death,
generally within 3 years of diagnosis. Sporadic cases of
this disorder are more common and can be caused by
the appetite-suppressant drugs phentermine and fenflur-
amine, which, in combination, are known as “phen-
fen.” Because of these effects, phen-fen is no longer avail-
able in combination. BMPR2 is a cell-signaling protein
that plays a role in lung development, and the mutations
in this gene are believed to reduce signaling in the BMP
pathway. This, in turn, could lead to the overprolifer-
ation of cells, in pulmonary arterioles, that causes the
symptoms of PPH. Delineation of this signaling pathway
will lead to a better understanding of the disease process
of familial PPH, and it will also help doctors to better
identify those at risk for developing the disorder.
KATHRYN BEAUREGARD
Editorial Fellow
